What To Know About The European Biotech Act

Cross-border trial access looks simple on paper: a study opens in one EU country, and an eligible patient in another may be able to join. In practice, that patient still has to navigate travel, unfamiliar documents, reimbursement, caregiver support, and language barriers before ever reaching the site. For people living with rare diseases, rare cancers, childhood conditions, or life-threatening illnesses, these gaps often determine whether a trial is truly reachable — because the expertise and infrastructure they need may sit across a border, not within it. A new leaflet on the EU Biotech Act puts this tension into the policy conversation: while the Act aims to speed approvals and improve cooperation between Member States, it does not yet give patients a clear legal path to enrolling in a trial abroad.

Left unaddressed, that gap shifts pressure onto sites and coordinators, who end up improvising travel, reimbursement, and documentation answers under time pressure — often after a patient has already been identified. Sponsors and CROs planning studies with potential cross-border participants should build the travel, reimbursement, documentation, and communication model before recruitment begins, so that an eligible patient's nearest realistic trial option becomes one they can actually use.